Erratum: Fragile sites are preferential targets for integrations of MLV vectors in gene therapy (Gene Therapy (2006) vol. 13 (1057-1059) 10.1038/sj.gt.3302752);Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

Gene Therapy

Volumn 13, Issue 13, 2006, Pages 1057-1059

  Bester, A C ^a   Schwartz, M ^a   Schmidt, M ^b   Garrigue, A ^c   Hacein Bey Abina, S ^c,d   Cavazzana Calvo, M ^c,d   Ben Porat, N ^a   Von Kalle, C ^b,e   Fischer, A ^c,f   Kerem, B ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Fragile sites; Leukemia; LMO2; Viral integration

Indexed keywords

DNA; VIRUS VECTOR;

ARTICLE; CHROMOSOME 11P; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA; MURINE LEUKEMIA VIRUS; PRIORITY JOURNAL; PROTO ONCOGENE; RISK BENEFIT ANALYSIS; TUMOR; VIRUS DNA CELL DNA INTERACTION; X CHROMOSOME LINKAGE;

MURINE LEUKEMIA VIRUS;

EID: 33745225238     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302904     Document Type: Erratum

References (12)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
2. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
3. Kaiser J. Gene therapy. Panel urges limits on X-SCID trials. Science 2005; 307: 1544-1545.
4. Popescu NC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett 2003; 192: 1-17.
5. Glover TW, Berger C, Coyle J, Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 1984; 67: 136-142.
6. Hellman A, Rahat A, Scherer SW, Darvasi A, Tsui LC, Kerem B. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol 2000; 20: 4420-4427.
7. Le Beau MM, Rassool FV, Neilly ME, Espinosa III R, Glover TW, Smith DI et al. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: Implications for the mechanism of fragile site induction. Hum Mol Genet 1998; 7: 755-761.
8. Wang L, Darling J, Zhang JS, Huang H, Liu W, Smith DI. Allele-specific late replication and fragility of the most active common fragile site, FRA3B. Hum Mol Genet 1999; 8: 431-437.
9. Schmidt M, Zickler P, Hoffmann G, Haas S, Wissler M, Muessig A et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 2002; 100: 2737-2743.
10. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
11. Panet A, Cedar H. Selective degradation of integrated murine leukemia proviral DNA by deoxyribonucleases. Cell 1977; 11: 933-940.
12. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.